01318nam 2200337z- 450 991069441960332120080611090213.0(CKB)5860000000018176(BIP)022723652(EXLCZ)99586000000001817620220406c2008uuuu -u- -engAssessing the impact of a safe and equitable biosimilar policy in the United States hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 2, 20071 online resource (vi, 184 p.) ill0-16-080887-1 Assessing the Impact of a Safe and Equitable Biosimilar Policy in the United StatesBiologicalsUnited StatesPharmaceutical biotechnologyUnited StatesGeneric drugsUnited StatesBiologicalsPharmaceutical biotechnologyGeneric drugsMedicalTechnology & engineeringBiologicalsPharmaceutical biotechnologyGeneric drugsBOOK9910694419603321Assessing the impact of a safe and equitable biosimilar policy in the United States3190062UNINA